Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency

Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency

Madhvi Rajpurkar,1 David L Cooper2 1Division of Hematology/Oncology, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children’s Hospital of Michigan, Detroit, MI, USA; 2Clinical, Medical and Regulatory Affairs, Novo Nordisk Inc., Plainsboro, NJ, US...

Full description

Bibliographic Details
Main Authors:	Rajpurkar M, Cooper DL
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	Journal of Blood Medicine
Subjects:	rFVIIa continuous infusion surgery bleeding
Online Access:	https://www.dovepress.com/continuous-infusion-of-recombinant-activated-factor-vii-a-review-of-da-peer-reviewed-article-JBM

Similar Items

Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
by: Aly Makram Habib, et al.
Published: (2016-10-01)

Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience
by: Nicolas Morel, et al.
Published: (2012-01-01)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
by: Dario Nicosia, et al.
Published: (2019-04-01)

Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures
by: Končar Igor B., et al.
Published: (2008-01-01)

Recombinant Activated Factor VII Treatment of Life-Threatening Rectus Sheath Hematoma in a Patient Receiving Enoxaparin, Aspirin, and Clopidogrel: A Case Report
by: Isawaruk Poonsawas, et al.
Published: (2020-07-01)

Uso del factor VII activado recombinante en pacientes no hemofílicos en Cuba Use of the recombinant activated factor VII in non-hemophilic patients in Cuba
by: Olga Agramonte Llanes, et al.
Published: (2008-12-01)

Use of recombinant factor VIIa for emergency reversal of anticoagulation
by: Ingerslev J, et al.
Published: (2007-01-01)

Adaptation of recombinant activated factor VII in the treatment of acquired haemophilia A: Results from a prospective study (ACQUI-7) in France
by: Benoît Guillet, et al.
Published: (2021-01-01)

Uso del factor VII activado recombinante en pacientes no hemofílicos en Cuba
by: Olga Agramonte Llanes, et al.

BUDGET IMPACT ANALYSIS OF INHIBITOR HAEMOPHILIA A THERAPY WITH BYPASSING AGENTS
by: Konstantin Tachkov, et al.
Published: (2019-04-01)

Uso del FVII activado recombinante en la enfermedad de Rendú-Osler-Weber o telangiectasia hemorrágica hereditaria y sangramiento digestivo: Primer caso comunicado en Cuba Use of recombinat activated factor VII in Rendú-Osler-Weber's disease or hereditary hemorrhagic talangiectasia and digestive bleeding: First case reported in Cuba
by: Olga M Agramonte Llanes, et al.
Published: (2008-12-01)

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury
by: Bobby Kim, et al.
Published: (2014-01-01)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
by: Nina Haagenrud Schultz, et al.
Published: (2021-07-01)

Acquired haemophilia: a case report and a clinical review
by: Lucia Todaro, et al.
Published: (2013-04-01)

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
by: Francesco Demartis, et al.
Published: (2017-07-01)

Successful non-standard approaches to massive hemoptysis in invasive pulmonary aspergillosis
by: Mitrović Mirjana, et al.
Published: (2012-01-01)

Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
by: Peltier S, et al.
Published: (2020-09-01)

Current management of massive hemorrhage in trauma
by: Johansson Pär I, et al.
Published: (2012-07-01)

Utilisation du facteur VII recombinant activé pour contrôler le saignement en chirurgie cardiaque : études cliniques observationnelles et études expérimentales
by: Durand, Marion
Published: (2010)

Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump
by: Per Rexen, et al.
Published: (2019-01-01)

Development and Applications of Recombinant Activated Factor VII
by: Nutjeera Intasai
Published: (2017-09-01)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
by: Johnny Mahlangu, et al.
Published: (2021-08-01)

Congenital factor VII deficiency: When to suspect?
by: Ankit Ranjan, et al.
Published: (2016-01-01)

The Challenge of Hemorrhagic Shock Management During Low-Molecular-Weight Heparin Treatment
by: Morotti A, et al.
Published: (2020-03-01)

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven&reg;)
by: Bartosh NS, et al.
Published: (2013-03-01)

Continuous wound infusion as an alternative to continuous epidural infusion for postoperative analgesia in renal transplant surgery: A prospective randomized controlled trial
by: Vinitha Narayan, et al.
Published: (2021-01-01)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
by: Masahiro Takeyama, et al.
Published: (2020-10-01)

Origin and Role of Factor Viia
by: Khandekar, Gauri
Published: (2013)

Partial transurethral prostatectomy in patient with congenital factor VII deficiency
by: Stojiljković Ljuba, et al.
Published: (2010-01-01)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
by: Linari S, et al.
Published: (2020-05-01)

Effect of activated recombinant factor VII versus tranexamic acid infusion on bleeding during spine surgery, randomized, controlled, double blinded trial
by: Hossam A. ELShamaa, et al.
Published: (2015-04-01)

Minimum infusion rate and adrenocortical function after continuous infusion of the novel etomidate analog ET-26-HCl in rats
by: Junli Jiang, et al.
Published: (2017-09-01)

Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report
by: Xiong Wang, et al.
Published: (2018-09-01)

Efficacy and Safety of Continuous Infusion of Vancomycin in Children: A Systematic Review
by: Marta Alonso-Moreno, et al.
Published: (2021-07-01)

Prostasin and hepatocyte growth factor B in factor VIIa generation: Serine protease knockdowns in zebrafish
by: Gauri Khandekar, et al.
Published: (2020-10-01)

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
by: Ampaiwan Chuansumrit, et al.
Published: (2010-03-01)

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
by: P&auml;r I Johansson, et al.
Published: (2010-06-01)

Aortic valve and coronary artery bypass surgery in a patient with factor VII deficiency
by: Larissa Henze, et al.
Published: (2021-01-01)

Uso de fator VII recombinante ativado para tratamento e profilaxia de grandes sangramentos Use of recombinant activated factor VII for treatment and prophylaxis of major bleeding
by: Flávio Augusto Henriques Vince, et al.
Published: (2009-09-01)

Recombinant-activated factor VII in the paediatric cardiac surgery: Single unit experience
by: Vijay Agarwal, et al.
Published: (2012-01-01)

Cannot write session to /tmp/vufind_sessions/sess_hcs9llrtbb3r9h3244revl7988